Shared on29 Jul 25Fair value Increased 10%
The consensus price target for InnoCare Pharma has increased to HK$13.51, underpinned by notable improvements in net profit margin and higher future P/E expectations. What's in the News InnoCare received IND approval to initiate a clinical trial for its novel B7-H3 targeted ADC (ICP-B794) for various solid tumors, further strengthening its solid tumor pipeline alongside other precision medicine candidates like zurletrectinib.
Shared on01 May 25Fair value Increased 1.83%
AnalystConsensusTarget has increased future PE multiple from 46.2x to 52.1x.
Shared on24 Apr 25Fair value Increased 4.07%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 22%
AnalystConsensusTarget has increased future PE multiple from 36.2x to 44.4x.
Shared on09 Apr 25Fair value Decreased 15%
AnalystConsensusTarget has increased profit margin from 15.6% to 17.9%, decreased future PE multiple from 40.8x to 36.2x and increased shares outstanding growth rate from -0.1% to -0.0%.
Shared on02 Apr 25Fair value Decreased 8.20%
AnalystConsensusTarget has decreased future PE multiple from 54.5x to 40.8x.